QC
SNDX icon

Quent Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Quent Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-59
Closed -$1K – 1360
2022
Q3 		$1K Hold
59
– – ﹤0.01% 1178
2022
Q2 		$1K Hold
59
– – ﹤0.01% 1128
2022
Q1 		$1K Buy
+59
New +$993 ﹤0.01% 1218

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Quent Capital's SNDX Position: Q4 2022 in Review

Quent Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2022, closing a stake of 59 shares — an estimated $1K sold.

Quent Capital first reported a position in SNDX in Q1 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 159 funds tracked by Wall St. Rank hold SNDX as of Q4 2022.

  • Quent Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Quent Capital sold 59 Syndax Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Quent Capital first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Quent Capital's Syndax Pharmaceuticals position peaked at $1K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2022.

Based on Quent Capital's 13F filing for Q4 2022, filed 19 Jan 2023.